P. D. Delgado-lopez, C. , and E. M. , Survival in glioblastoma: a review on the impact of treatment modalities, Clin Transl Oncol, vol.18, pp.1062-71, 2016.

R. Stupp, W. P. Mason, M. J. Van-den-bent, M. Weller, B. Fisher et al.,

K. Belanger, A. A. Brandes, C. Marosi, U. Bogdahn, J. Curschmann et al.,

, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, N Engl J Med, vol.352, pp.987-96, 2005.

W. Ma, N. Li, Y. An, C. Zhou, C. Bo et al., Effects of Temozolomide and Radiotherapy on Brain Metastatic Tumor: A Systematic Review and Meta-Analysis, World Neurosurg, vol.92, pp.197-205, 2016.

S. K. Singh, C. Hawkins, I. D. Clarke, J. A. Squire, J. Bayani et al.,

M. D. Cusimano and P. B. Dirks, Identification of human brain tumour initiating cells, Nature, vol.432, pp.396-401, 2004.

J. D. Lathia, S. C. Mack, E. E. Mulkearns-hubert, C. L. Valentim, and J. N. Rich, Cancer stem cells in glioblastoma, Genes Dev, vol.29, pp.1203-1220, 2015.

M. K. Kang and S. K. Kang, Tumorigenesis of chemotherapeutic drug-resistant cancer stem-like cells in brain glioma, Stem Cells Dev, vol.16, pp.837-884, 2007.

F. Pajonk, E. Vlashi, and W. H. Mcbride, Radiation resistance of cancer stem cells: the 4

, R's of radiobiology revisited, Stem Cells, vol.28, pp.639-687, 2010.

D. Beier, J. B. Schulz, and C. P. Beier, Chemoresistance of glioblastoma cancer stem cells--much more complex than expected, Mol Cancer, vol.10, p.128, 2011.

J. Wang, T. P. Wakeman, J. D. Lathia, A. B. Hjelmeland, X. F. Wang et al.,

B. A. Sullenger, Notch promotes radioresistance of glioma stem cells, Stem Cells, vol.28, pp.17-28, 2010.

S. F. Murphy, R. T. Varghese, S. Lamouille, S. Guo, K. J. Pridham et al., Connexin, vol.43

, Inhibition Sensitizes Chemoresistant Glioblastoma Cells to Temozolomide, Cancer Res, vol.76, pp.139-188, 2016.

K. Bhat, V. Balasubramaniyan, B. Vaillant, R. Ezhilarasan, and K. Hummelink,

F. Hollingsworth, K. Wani, L. Heathcock, J. D. James, L. D. Goodman et al.,

, Mesenchymal differentiation mediated by NF-kappaB promotes radiation resistance in glioblastoma, Cancer Cell, vol.24, pp.331-377, 2013.

V. A. Venur, D. M. Peereboom, and M. S. Ahluwalia, Current medical treatment of glioblastoma, Cancer Treat Res, vol.163, pp.103-118, 2015.

D. A. Reardon, A. Desjardins, J. J. Vredenburgh, S. Gururangan, and A. H. Friedman,

J. E. Herndon, M. J. Norfleet, J. A. Mclendon, R. E. Sampson, J. H. Friedman et al., Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma, J Neurooncol, vol.96, pp.219-249, 2010.

D. R. Emlet, P. Gupta, M. Holgado-madruga, D. Vecchio, C. A. Mitra et al.,

G. Li, K. C. Jensen, H. Vogel, L. W. Xu, S. S. Skirboll et al., Targeting a glioblastoma cancer stem-cell population defined by EGF receptor variant III, Cancer Res, vol.74, pp.1238-1287, 2014.

N. Ahmed, V. S. Salsman, Y. Kew, D. Shaffer, S. Powell et al.,

H. E. Heslop, S. Gottschalk, C. E. Brown, R. Starr, B. Aguilar et al., HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors, Clin Cancer Res, vol.16, pp.474-85, 2010.

S. J. Forman and M. C. Jensen, Stem-like tumor-initiating cells isolated from IL13Ralpha2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T Cells, Clin Cancer Res, vol.18, pp.2199-209, 2012.

M. Hegde, A. Corder, K. K. Chow, M. Mukherjee, A. Ashoori et al.,

D. S. Baskin, F. A. Merchant, V. S. Brawley, T. T. Byrd, and S. Krebs, Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma, Mol Ther, vol.21, pp.2087-101, 2013.

M. Hegde, M. Mukherjee, Z. Grada, A. Pignata, D. Landi et al., Tandem CAR T cells targeting HER2 and IL13Ralpha2 mitigate tumor antigen escape, J Clin Invest, vol.126, pp.3036-52, 2016.

D. M. O'rourke, M. P. Nasrallah, A. Desai, J. J. Melenhorst, K. Mansfield et al.,

. Jjd, M. Martinez-lage, S. Brem, E. Maloney, A. Shen et al.,

J. Fleurence, D. Cochonneau, S. Fougeray, L. Oliver, F. Geraldo et al., EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma, Sci Transl Med, vol.9, 2017.

M. Dorvillius, D. Loussouarn, F. Vallette, F. Paris, and S. Birkle, Targeting and killing glioblastoma with monoclonal antibody to O-acetyl GD2 ganglioside, Oncotarget, vol.7, pp.41172-85, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-01319327

S. Faraj, M. Bahri, S. Fougeray, A. El-roz, J. Fleurence et al.,

E. Thebaud, F. Paris, and S. Birkle, Neuroblastoma chemotherapy can be augmented by immunotargeting O-acetyl-GD2 tumor-associated ganglioside, Oncoimmunology, vol.7, p.1373232, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-01596068

S. C. Yeh, P. Y. Wang, Y. W. Lou, K. H. Khoo, M. Hsiao et al., Glycolipid GD3 and GD3 synthase are key drivers for glioblastoma stem cells and tumorigenicity, Proc Natl Acad Sci U S A, vol.113, pp.5592-5599, 2016.

K. Oizel, C. Chauvin, L. Oliver, C. Gratas, F. Geraldo et al., Efficient Mitochondrial Glutamine Targeting Prevails Over Glioblastoma Metabolic Plasticity, Clin Cancer Res, vol.23, pp.6292-304, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-01595798

F. Denizot and R. Lang, Rapid colorimetric assay for cell growth and survival

, Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability, J Immunol Methods, vol.89, pp.271-278, 1986.

T. C. Chou and P. Talalay, Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors, Adv Enzyme Regul, vol.22, pp.27-55, 1984.

M. Bahri, J. Fleurence, S. Faraj, B. Mostefa-daho, M. Fougeray et al.,

, Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of

, Antibody-drug Synergism Using the Combination Index Equation, J Vis Exp, 2019.

Y. Hu and G. K. Smyth, ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays, J Immunol Methods, vol.347, pp.70-78, 2009.

M. E. Hegi, A. C. Diserens, S. Godard, P. Y. Dietrich, L. Regli et al.,

, methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide, Clin Cancer Res, vol.10, pp.1871-1875, 2004.

D. M. Kokkinakis, A. G. Brickner, J. M. Kirkwood, X. Liu, J. E. Goldwasser et al.,

A. , S. C. Bocangel, D. Chada, and S. , Mitotic arrest, apoptosis, and sensitization to chemotherapy of melanomas by methionine deprivation stress, Mol Cancer Res, vol.4, pp.575-89, 2006.

N. Alvarez-rueda, A. Desselle, D. Cochonneau, T. Chaumette, and B. Clemenceau,

S. Leprieur, G. Bougras, S. Supiot, J. M. Mussini, J. Barbet et al., A monoclonal antibody to O-acetyl-GD2 ganglioside and not to GD2 shows potent anti-tumor activity without peripheral nervous system cross-reactivity, Front Oncol, vol.6, p.55, 2011.

J. I. Bastien, K. A. Mcneill, and H. A. Fine, Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date, Cancer, vol.121, pp.502-518, 2015.

S. K. Singh, I. D. Clarke, M. Terasaki, V. E. Bonn, C. Hawkins et al.,

, Identification of a cancer stem cell in human brain tumors, Cancer Res, vol.63, pp.5821-5829, 2003.

R. M. Gangemi, F. Griffero, D. Marubbi, M. Perera, M. C. Capra et al.,

Z. G. Gl, A. Daga, and G. Corte, SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity, Stem Cells, vol.27, pp.40-48, 2009.

B. Wu, C. Sun, F. Feng, M. Ge, and L. Xia, Do relevant markers of cancer stem cells CD133 and Nestin indicate a poor prognosis in glioma patients? A systematic review and meta-analysis, J Exp Clin Cancer Res, vol.34, p.44, 2015.

, Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials, Cancer Treat Rev, vol.23, pp.35-61, 1997.

M. Okada, N. Ogino, M. Matsumura, Y. Honda, and Y. Nagai, The process of subretinal strand formation, Jpn J Ophthalmol, vol.36, pp.222-256, 1992.

X. Huang, H. D. Halicka, and Z. Darzynkiewicz, Detection of histone H2AX

, phosphorylation on Ser-139 as an indicator of DNA damage (DNA double-strand breaks)

, This article is protected by copyright. All rights reserved, Curr Protoc Cytom, vol.7, p.27, 2004.

U. Jarry, C. Chauvin, N. Joalland, A. Leger, S. Minault et al., Stereotaxic administrations of allogeneic human Vgamma9Vdelta2 T cells efficiently control the development of human glioblastoma brain tumors, Oncoimmunology, vol.5, p.1168554, 2016.

C. Liu, D. W. Voth, P. Rodina, L. R. Shauf, and G. Gonzalez, A comparative study of the pathogenesis of western equine and eastern equine encephalomyelitis viral infections in mice by intracerebral and subcutaneous inoculations, J Infect Dis, vol.122, pp.53-63, 1970.

A. B. Nair and S. Jacob, A simple practice guide for dose conversion between animals and human, J Basic Clin Pharm, vol.7, pp.27-31, 2016.

T. Reya, S. J. Morrison, M. F. Clarke, and I. L. Weissman, Stem cells, cancer, and cancer stem cells, Nature, vol.414, pp.105-116, 2001.

K. Kramer, W. L. Gerald, B. H. Kushner, S. M. Larson, M. Hameed et al.,

G. Disialoganglioside, D2) loss following monoclonal antibody therapy is rare in neuroblastoma, Clin Cancer Res, vol.4, pp.2135-2144, 1998.

N. Yuki, M. Yamada, Y. Tagawa, H. Takahashi, S. Handa et al., Pathogenesis of the neurotoxicity caused by anti-GD2 antibody therapy, J Neurol Sci, vol.149, pp.127-157, 1997.

I. Morra, G. Cavallo, S. Reguzzi, G. Pescarmona, and A. Ponzetto, Glioblastoma cancer stem cells: heterogeneity, microenvironment and related therapeutic strategies, Cell Biochem Funct, vol.28, pp.343-51, 2010.

J. T. Kemshead, D. H. Jones, L. Lashford, J. Prichard, I. Gordon et al.,

H. B. Coakham, 131-I coupled to monoclonal antibodies as therapeutic agents for neuroectodermally derived tumors: fact or fiction?, Cancer Drug Deliv, vol.3, pp.25-43, 1986.

B. Auffinger, A. L. Tobias, Y. Han, G. Lee, D. Guo et al., Conversion of differentiated cancer cells into cancer stem-like cells in a glioblastoma model after primary chemotherapy, Cell Death Differ, vol.21, pp.1119-1150, 2014.

P. Wersall, I. Ohlsson, P. Biberfeld, V. P. Collins, S. Von-krusenstjerna et al.,

H. Mellstedt and J. Boethius, Intratumoral infusion of the monoclonal antibody, mAb 425, against the epidermal-growth-factor receptor in patients with advanced malignant glioma, Cancer Immunol Immunother, vol.44, pp.157-64, 1997.